Drug Sales In The Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-

tD33NAt

Active member
Joined
Mar 24, 2008
Messages
12,519
Reaction score
0
Points
36
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the leukemia market will be driven mostly by chronic myelogenous leukemia (CML) therapies (Novartis's Gleevec and Tasigna and Bristol-Myers Squibb's Sprycel) and chronic lymphocytic leukemia (CLL) therapies (Biogen Idec/Roche's Rituxan and Cephalon's Treanda) until 2015, when patent and orphan-drug exclusivities of key brands will impact the sustainability of this growth...


xjTlB7gX1iI


More...
 
Back
Top